LUNGevity Foundation· @LUNGevity · X·· 2026-04-18Score60
Body
We are kicking off our #AACR26 coverage with ED07. What a fantastic way to start! Session ED07 dives into mechanisms of resistance to targeted & IO therapies, covering RAS inhibitors in lung, colon & pancreatic cancer + checkpoint therapy resistance in head & neck cancers.
Heat 11 · 7 likes · 1 reply · 3 reposts
Source: LUNGevity Foundation · x.com
